AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Theriva Biologics reports Q2 2025 financials, $12.1mln cash, VCN-01 data positive.
ByAinvest
Monday, Aug 11, 2025 8:17 am ET1min read
• Theriva Biologics releases positive topline data from VIRAGE Phase 2b study of VCN-01. • Expanded data to be presented at ESMO 2025 Congress in October. • VCN-01 shows potential in retinoblastoma with Phase 1 safety and clinical outcome data. • Cash and cash equivalents of $12.1 million as of June 30, 2025. • Expected cash runway into Q1 2026.
Theriva Biologics (NYSE American: TOVX) has announced positive topline data from its VIRAGE Phase 2b study of VCN-01. The study, which focuses on patients with pancreatic ductal adenocarcinoma (PDAC) metastásico, showed promising results in terms of survival, progression-free survival, and response duration compared to standard gemcitabine/nab-paclitaxel treatment [1].The company expects to present expanded data from the VIRAGE study at the European Society for Medical Oncology (ESMO) 2025 Congress in October. Additionally, VCN-01 demonstrated potential in the treatment of retinoblastoma, with positive clinical and safety outcomes from a Phase 1 study presented at the 2025 American Society of Clinical Oncology (ASCO) meeting [1].
Theriva Biologics reported $12.1 million in cash and cash equivalents as of June 30, 2025, with sufficient liquidity to fund operations until the first quarter of 2026 [1]. The company's CEO, Steven A. Shallcross, expressed optimism about the progress made in the first half of 2025 and the potential for VCN-01 to advance into Phase 3 clinical trials for PDAC and other indications [1].
References:
[1] Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2025. [https://www.globenewswire.com/news-release/2025/08/11/3130834/0/es/Theriva-Biologics-presenta-los-aspectos-operativos-m%C3%A1s-destacados-y-los-resultados-financieros-del-segundo-trimestre-de-2025.html](https://www.globenewswire.com/news-release/2025/08/11/3130834/0/es/Theriva-Biologics-presenta-los-aspectos-operativos-m%C3%A1s-destacados-y-los-resultados-financieros-del-segundo-trimestre-de-2025.html)
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet